Aviado · Research
Longevity Daily
Thursday, April 23, 2026
Listen
Today's Brief
Today's strongest stories share a throughline: what you do in midlife matters enormously for cognitive health. The lead story — a 10-year longitudinal study — finds diverse lifestyle activities beat the APOE ε4 gene in predicting Alzheimer's risk, a finding more actionable than any genetic test. A major independent review meanwhile challenges the efficacy of today's leading Alzheimer's drugs, and a University of Aberdeen gut-biopsy discovery suggests neurodegeneration may be detectable years before brain symptoms appear. Rounding out the issue: why rapamycin may blunt your exercise gains, and how the immune system ages along strikingly different paths in men versus women.
10 stories7 peer-reviewed2 trials
Cognitive Health & Neuroprotection
Midlife Hobbies Outperform the APOE ε4 Gene in Predicting Alzheimer's Risk
A 10-year longitudinal study finds that engaging in diverse lifestyle activities — reading, socializing, learning new skills — in midlife is a stronger predictor of cognitive health than carrying the APOE ε4 gene, the most well-known Alzheimer's risk variant. This is a pivotal finding: your daily choices appear to outweigh your genetic hand when it comes to brain aging. If you're APOE ε4 positive or simply worried about dementia, this study makes a compelling case that structured hobbies and social engagement deliver higher ROI than most interventions. Note: the study is observational, so causation can't be fully established — but a decade of consistent data is hard to ignore.
Read more →AI Flags Appendix Removal and Gut Disruption as Alzheimer's Risk Factors
A large-scale AI analysis has identified appendix removal and long-term gut microbiome disruption as meaningful predictors of Alzheimer's risk, reinforcing the gut-brain axis hypothesis. The finding suggests that events earlier in life — even surgical ones — may shape brain aging decades later. While this is a data-driven correlation study requiring further clinical validation, it adds important weight to the case for actively protecting microbiome health throughout life.
Read more →Alzheimer's Drugs Offer Little Benefit, Major Review Finds — and the Problem Goes Deeper Than the Science
A comprehensive new review of leading anti-amyloid Alzheimer's drugs — the class including lecanemab and donanemab — concludes they "probably result in little to no difference" across key measures of dementia severity. The authors argue the problems extend beyond the science itself, pointing to how regulatory pressures and clinical trial endpoints are constructed to favor approval. If you or a family member is navigating treatment decisions, this is a critical read — and a prompt to ask hard questions about what "slowing decline" actually means in practice.
Read more →4 Common Medications That May Raise Dementia Risk — and a Few That May Help
Research reviewed by The New York Times identifies several widely-used medications — including certain anticholinergics and sleep aids — that appear to meaningfully raise long-term dementia risk, while others (statins, blood pressure drugs) may be protective. This is especially actionable if you or someone you care for takes any of these drugs regularly. It's worth a conversation with your physician about lower-risk alternatives, particularly for drugs with strong anticholinergic effects.
Read more →Supplements & Compounds
Rapamycin May Blunt the Exercise Response in Older Adults
A new human study suggests rapamycin — the most-studied longevity drug in animal models — may interfere with the body's adaptation to exercise in older adults, potentially diminishing one of the most powerful pro-longevity interventions available. This is a significant caveat for the growing community using low-dose rapamycin for healthspan purposes. The study has limitations including sample size and dosing variation, and the tradeoff between rapamycin's longevity effects and exercise blunting requires further investigation before firm conclusions can be drawn.
Read more →Research & Papers
Immune Aging Follows Strikingly Different Paths in Men and Women
A new investigation into age-related immune changes found that females show significantly greater shifts in immune cell populations and gene expression over time compared to males. This has real implications for how age-related diseases — from autoimmunity to infection susceptibility — manifest differently by sex. The finding reinforces why sex-specific approaches to immune health and longevity medicine aren't just preferable but scientifically necessary.
Read more →Routine Gut Biopsies May Detect Parkinson's and Dementia Years Before Symptoms
University of Aberdeen researchers have found that standard gut tissue samples — already collected during routine colonoscopies — may predict Parkinson's and dementia risk years before neurological symptoms appear. The discovery centers on protein aggregates found in gut tissue that mirror those seen in the brain, potentially opening an early intervention window using existing medical infrastructure. If validated in larger studies, this could transform routine GI procedures into a powerful neurological screening tool.
Read more →Lifestyle & Nutrition
Midlife Fitness Delays Chronic Disease Onset by at Least 1.5 Years
Tracking 24,500 adults, researchers found that higher fitness levels in midlife delayed the onset of chronic illness — including heart disease and diabetes — by at least 1.5 years compared to low-fitness peers. Critically, the study frames the benefit as healthspan (years lived without disease), not just lifespan, suggesting fitness's biggest payoff is quality of life. The effect was dose-dependent: even moderate fitness improvements delivered meaningful gains over sedentary baselines.
Read more →Industry & Policy
Cell-Based Therapy Enters Clinical Trial for Parkinson's Disease
A new clinical trial is testing cell-based therapies as a treatment for Parkinson's disease, representing a meaningful step toward regenerative approaches to neurodegeneration. The trial reflects growing momentum in applying rejuvenative biology to conditions previously considered irreversible. Early-stage trials typically take years to produce efficacy data, but the underlying mechanism is scientifically credible and worth tracking.
Read more →BioAge's Metabolic Aging Drug BGE-102 Clears Phase 1 Safety Bar
BioAge Labs has reported positive Phase 1 safety and tolerability data for BGE-102, its lead candidate targeting the biology of aging to treat metabolic disease. Phase 1 establishes safety, not efficacy, but a clean readout is a required hurdle before larger trials can proceed. BioAge's approach — using human aging biology to identify drug targets — represents one of the more scientifically grounded pipelines currently in the longevity biotech space.
Read more →